Patrick Dolezal
Stock Analyst at LifeSci Capital
(4.11)
# 1,626
Out of 5,004 analysts
213
Total ratings
38.5%
Success rate
8.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Dolezal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRZN Surrozen | Rated: Buy | $46 → $54 | $29.54 | +82.80% | 9 | Sep 26, 2026 | |
| ENTX Entera Bio | Initiated Coverage: Buy | $10 | $2.75 | +264.30% | 1 | Sep 23, 2026 | |
| RCKT Rocket Pharmaceuticals | Reiterated: Buy | $12 | $2.60 | +362.43% | 47 | Sep 15, 2026 | |
| IMMX Immix Biopharma | Rated: Buy | $19 → $26 | $10.97 | +137.01% | 2 | Sep 12, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $104 | $35.93 | +189.45% | 14 | Sep 8, 2026 | |
| ACHV Achieve Life Sciences | Reiterated: Buy | $17 | $7.54 | +125.46% | 5 | Sep 3, 2026 | |
| VTVT vTv Therapeutics | Initiated Coverage: Buy | $60 | $30.21 | +98.61% | 1 | Sep 2, 2026 | |
| IBIO iBio, Inc. | Reiterated: Buy | $5 | $1.19 | +320.17% | 13 | Aug 28, 2026 | |
| SLGL Sol-Gel Technologies | Rated: Buy | $184 → $195 | $66.85 | +191.70% | 4 | Aug 22, 2026 | |
| KOD Kodiak Sciences | Reiterated: Buy | $65 → $85 | $32.35 | +162.75% | 12 | Aug 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 → $63 | $28.31 | +122.54% | 13 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $91 → $121 | $53.63 | +125.62% | 8 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $41 | $9.27 | +342.29% | 10 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 | $75.69 | n/a | 21 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $25.54 | n/a | 25 | Nov 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $3.08 | n/a | 12 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $16 | $0.6096 | n/a | 5 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $31.10 | n/a | 1 | Dec 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $25 | $3.37 | n/a | 2 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €10.00 → €25.00 | €2.85 | n/a | 8 | Jun 16, 2020 |
Surrozen
Sep 26, 2026
Rated: Buy
Price Target: $46 → $54
Current: $29.54
Upside: +82.80%
Entera Bio
Sep 23, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $2.75
Upside: +264.30%
Rocket Pharmaceuticals
Sep 15, 2026
Reiterated: Buy
Price Target: $12
Current: $2.60
Upside: +362.43%
Immix Biopharma
Sep 12, 2026
Rated: Buy
Price Target: $19 → $26
Current: $10.97
Upside: +137.01%
Structure Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $104
Current: $35.93
Upside: +189.45%
Achieve Life Sciences
Sep 3, 2026
Reiterated: Buy
Price Target: $17
Current: $7.54
Upside: +125.46%
vTv Therapeutics
Sep 2, 2026
Initiated Coverage: Buy
Price Target: $60
Current: $30.21
Upside: +98.61%
iBio, Inc.
Aug 28, 2026
Reiterated: Buy
Price Target: $5
Current: $1.19
Upside: +320.17%
Sol-Gel Technologies
Aug 22, 2026
Rated: Buy
Price Target: $184 → $195
Current: $66.85
Upside: +191.70%
Kodiak Sciences
Aug 15, 2026
Reiterated: Buy
Price Target: $65 → $85
Current: $32.35
Upside: +162.75%
Aug 11, 2026
Reiterated: Buy
Price Target: $65 → $63
Current: $28.31
Upside: +122.54%
Aug 8, 2026
Rated: Buy
Price Target: $91 → $121
Current: $53.63
Upside: +125.62%
Aug 8, 2026
Reiterated: Buy
Price Target: $45 → $41
Current: $9.27
Upside: +342.29%
Dec 11, 2023
Rated: Buy
Price Target: $60
Current: $75.69
Upside: n/a
Nov 11, 2023
Reiterated: Buy
Price Target: $6
Current: $25.54
Upside: n/a
Aug 10, 2023
Rated: Buy
Price Target: $14
Current: $3.08
Upside: n/a
Mar 9, 2023
Reiterated: Buy
Price Target: $17 → $16
Current: $0.6096
Upside: n/a
Dec 11, 2022
Reiterated: Buy
Price Target: $39
Current: $31.10
Upside: n/a
Mar 8, 2021
Reiterated: Buy
Price Target: $27 → $25
Current: $3.37
Upside: n/a
Jun 16, 2020
Reiterated: Buy
Price Target: €10.00 → €25.00
Current: €2.85
Upside: n/a